293780.KQ
AptaBio Therapeutics Inc. [293780.KQ] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
293780.KQ Stock Summary
Top 10 Correlated ETFs
293780.KQ
Top 10 Correlated Stocks
293780.KQ
In the News
293780.KQ Financial details
Company Rating
-
Market Cap
134.02B
Income
-19.1B
Revenue
323.87M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
-
Optionable
No
Shortable
Yes
Earnings
31 Jan 2023
P/E
-16.63
Forward P/E
-
PEG
-2.06
P/S
3567.74
P/B
4.04
P/C
-
P/FCF
-23.12
Quick Ratio
10.11
Current Ratio
13.13
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-856.45
EPS next Y
-
EPS next Q
-
EPS this Y
80.69%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
24.24%
Revenue last 5Y
-20.48%
Revenue Q/Q
3348.52%
EPS Q/Q
99.26%
-
-
-
-
SMA20
1.94%
SMA50
-9.79%
SMA100
14.3%
Inst Own
-
Inst Trans
-
ROA
-22%
ROE
-23%
ROC
-0.2%
Gross Margin
91%
Oper. Margin
-19558%
Profit Margin
-22309%
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
4935.0-13650.0
52W High
-47.91%
52W Low
+44.07%
RSI
46
Rel Volume
0.13
Avg Volume
144.05K
Volume
18.71K
Perf Week
-9.2%
Perf Month
-4.18%
Perf Quarter
-9.54%
Perf Half Y
-10.9%
-
-
-
-
Beta
2.012
-
-
Volatility
216.43%, 339.32%
Prev Close
0%
Price
7110
Change
-0.97%
Company Profile
- Volume Average 144.05K
- Market Capitalization 134.02B
- CEO Dr. Jin Lee Soo
- Headquarters Yongin-si,KR
- IPO Date 2019-06-12
-
Website
http://www.aptabio.com 
AptaBio Therapeutics Inc. discovers and develops selective inhibitors of the NOX family of enzymes and aptamer-based anti-cancer drugs. The company offers Lipofector-Q, Lipofector-EXT, Lipofector-2000, Lipofector-EZ, and Lipofector-pMAX Reagent for transfecting DNA or RNA into eukaryotic cells. Its product candidates include PX-115 for treating diabetic nephropathy; APX-1004 to treat diabetic retinopathy; and APX-311 for use in treating non-alcoholic steatohepatitis (NASH). The company was founded in 2009 and is based in Yongin-Si, South Korea.
